Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 128

1.

The 2015 Military Health System Research Symposium Awards.

Reilly PA.

Mil Med. 2017 Mar;182(S1):3-9. doi: 10.7205/MILMED-D-16-00340. No abstract available.

PMID:
28291445
2.

Issue Overview.

Reilly PA, Brininger TL.

Mil Med. 2017 Mar;182(S1):2. doi: 10.7205/MILMED-D-16-00388. No abstract available.

PMID:
28291444
3.

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.

Norris S, Ramael S, Ikushima I, Haazen W, Harada A, Moschetti V, Imazu S, Reilly PA, Lang B, Stangier J, Glund S.

Br J Clin Pharmacol. 2017 Feb 23. doi: 10.1111/bcp.13269. [Epub ahead of print]

PMID:
28230262
4.

Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysm.

Tomaszuk-Kazberuk A, Łopatowska P, Młodawska E, van Ryn J, Reilly PA, Pollack CV.

Pol Arch Intern Med. 2017 Jan 31;127(1):68-70. doi: 10.20452/pamw.3918. Epub 2017 Jan 31. No abstract available.

5.

Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.

Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J.

Am J Emerg Med. 2016 Nov;34(11S):26-32. doi: 10.1016/j.ajem.2016.09.050. Epub 2016 Sep 28. Review.

6.

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.

Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J.

Am J Med. 2016 Nov;129(11S):S64-S72. doi: 10.1016/j.amjmed.2016.06.007. Epub 2016 Aug 26.

7.

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).

Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L.

Circulation. 2016 Aug 23;134(8):589-98. doi: 10.1161/CIRCULATIONAHA.115.020950. Epub 2016 Aug 5.

PMID:
27496855
8.

The 2014 Military Health System Research Symposium Awards: Recognizing Those Pushing the Science Envelope.

Reilly PA.

Mil Med. 2016 May;181(5 Suppl):265-70. doi: 10.7205/MILMED-D-15-00513. No abstract available.

PMID:
27168583
9.

Publishing Military Medical Research: Appreciating the Process.

Hatzfeld JJ, Khalili RA, Hendrickson TL, Reilly PA.

Mil Med. 2016 May;181(5 Suppl):5-6. doi: 10.7205/MILMED-D-15-00517. No abstract available.

PMID:
27168546
10.

An assessment of mercury in estuarine sediment and tissue in Southern New Jersey using public domain data.

Ng K, Szabo Z, Reilly PA, Barringer JL, Smalling KL.

Mar Pollut Bull. 2016 Jun 15;107(1):22-35. doi: 10.1016/j.marpolbul.2016.04.027. Epub 2016 May 6.

PMID:
27158049
11.

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.

Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Kent AP, Pogue J, Spahr J, Clemens A, Noack H, Diener HC, Wallentin L, Yusuf S, Connolly SJ.

Europace. 2016 Jul;18(7):973-8. doi: 10.1093/europace/euv312. Epub 2016 Mar 3.

PMID:
26944733
12.

D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy.

Siegbahn A, Oldgren J, Andersson U, Ezekowitz MD, Reilly PA, Connolly SJ, Yusuf S, Wallentin L, Eikelboom JW.

Thromb Haemost. 2016 May 2;115(5):921-30. doi: 10.1160/TH15-07-0529. Epub 2016 Jan 28.

PMID:
26818781
13.

Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.

Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, Huber K, Reilly PA, Wallentin L, Oldgren J.

Am Heart J. 2015 Dec;170(6):1151-60. doi: 10.1016/j.ahj.2015.09.018. Epub 2015 Oct 3.

PMID:
26678637
14.

Reply: Anticoagulant-Related Nephropathy.

Böhm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L.

J Am Coll Cardiol. 2015 Dec 15;66(23):2682. doi: 10.1016/j.jacc.2015.09.080. No abstract available.

15.

Letter to the Editor: Managing Dabigatran-Related Bleeding.

Levy JH, Weitz JI, Bernstein RA, Eikelboom J, Hylek E, Huisman MV, Reilly PA, Steiner T, Kamphuisen P, Kam CW, Pollack CV Jr.

J Intensive Care Med. 2016 Jan;31(1):70-1. doi: 10.1177/0885066614542758. No abstract available.

PMID:
26663474
16.

Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score.

Hori M, Fukaya T, Kleine E, Reilly PA, Ezekowitz MD, Connolly SJ; RE-LY Investigators..

Circ J. 2015;79(10):2138-47. doi: 10.1253/circj.CJ-15-0594. Epub 2015 Aug 6.

17.

Idarucizumab for Dabigatran Reversal.

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI.

N Engl J Med. 2015 Aug 6;373(6):511-20. doi: 10.1056/NEJMoa1502000. Epub 2015 Jun 22.

18.

Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial.

Böhm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L.

J Am Coll Cardiol. 2015 Jun 16;65(23):2481-93. doi: 10.1016/j.jacc.2015.03.577.

19.

Novel oral anticoagulants and reversal agents: Considerations for clinical development.

Sarich TC, Seltzer JH, Berkowitz SD, Costin' J, Curnutte JT, Gibson CM, Hoffman M, Kaminskas E, Krucoff MW, Levy JH, Mintz PD, Reilly PA, Sager PT, Singer DE, Stockbridge N, Weitz JI, Kowey PR.

Am Heart J. 2015 Jun;169(6):751-7. doi: 10.1016/j.ahj.2015.03.010. Epub 2015 Mar 26.

PMID:
26027611
20.

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.

Pollack CV Jr, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, Huisman MV, Hylek E, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Sellke F, Stangier J, Steiner T, Wang B, Weitz JI.

Thromb Haemost. 2015 Jul;114(1):198-205. doi: 10.1160/TH15-03-0192. Epub 2015 May 28.

PMID:
26020620

Supplemental Content

Loading ...
Support Center